CDR-Life Inc.

Heading to BIO-Europe in Stockholm! Our CEO Christian Leisner will be discussing CDR-Life's innovative M-gager platform for solid tumors and autoimmune diseases, and our exciting progress in developing powerful, targeted T cell engager therapies. Want to meet up? Drop us a line! #BIOEurope

Thank you Brad Loncar for traveling to Zurich to interview Christian Leisner about CDR-Life's T cell engager (TCE) platform to target hard-to-treat tumors. There's never been a more exciting time in the industry and we are buoyed by our recent milestones of the first patient dosed with CDR404, a novel, bispecific and bivalent antibody fragment-based TCE targeting MAGE-A4, and our new clinical candidate targeting PRAME, CDR813. Check out the full interview!

The immunotherapy landscape for challenging cancers continues to evolve rapidly, as evidenced at #ESMO2024. Breakthroughs in MAGE-A4/8 targeting are particularly promising. We're proud to contribute to this momentum - last week, CDR-Life hit a key milestone with CDR404, our innovative antibody-derived, bivalent and bispecific T cell engager against MAGE-A4. Check out last week's release for more info! https://lnkd.in/e2VQrW4X

Exciting news! We're thrilled to announce significant progress in our M-gager® portfolio for solid tumors: *First patient dosed with CDR404, our novel T cell engager targeting MAGE-A4 in HLA-A*02:01+ patients with MAGE-A4+ solid cancers. *Introducing CDR813, our new development candidate targeting PRAME, a tumor-specific antigen expressed in various solid tumors. Be sure to check out our poster at ESMO! These milestones mark important steps in our quest to deliver innovative, antibody-fragment based immunotherapies for difficult-to-treat cancers. Learn more 👉https://lnkd.in/e2VQrW4X

#News: Boehringer Ingelheim advances BI 771716, a promising treatment for geographic atrophy (major cause of vision loss), after positive Phase 1 results. Using @CDR-Life's licensed tech, this antibody fragment penetrates all retinal layers, targeting key disease drivers. Excited for the potential for unprecedented efficacy!  #VisionResearch #BiotechInnovation"   Learn more 👉 https://lnkd.in/e2VQrW4X   Be sure to check out our growing pipeline of first-in-class therapy candidates addressing solid tumors and hematologic malignancies | https://lnkd.in/e2ME_tDq #RetinalDiseases #ClinicalResearch #RetinalHealth

Honored to be recognized by Labiotech.eu as a Swiss biotech to watch! Curious about our innovative T-cell engagers? Discover how we're harnessing the immune system to fight cancer at www.cdr-life.com.

Great news! CDR-Life Inc. expands its innovative cancer therapy portfolio with the addition of two highly tumor-targeted T cell engagers (TCE):   - CDR813: A powerhouse T cell engager targeting PRAME in HLA-A*02:01 patients. PRAME is a clinically validated pan-cancer target expressed in a broad set of tumors including non-small cell lung cancer, endometrial cancer, melanoma and ovarian cancer but not in normal tissue. This bi-valent, bi-specific antibody shows unparalleled potency and precision. - CDR505: Breaking new ground with a T cell engager for KK-LC-1 in HLA-A01 patients. This expands treatment possibilities beyond the common HLA-A02 focus to benefit a large patient population with high unmet need. These additions strengthen CDR-Life's mission to develop targeted cancer therapies for broader patient populations. Read more: https://bit.ly/4bldGNA

We are thrilled to announce the initiation of enrollment for the Phase 1 trial of CDR404, our lead program in development as a precision immunotherapy for solid tumors. The study was published as an online presentation at #ASCO24 Based on the company’s unique M-gager® technology, CDR404 is a first-of-its-kind, antibody-based bivalent and bispecific MAGE-A4 T-cell engager (TCE) for the treatment of MAGE-A4 positive solid tumors. The Phase I study evaluating CDR404 is actively enrolling at sites in the U.S. and Europe. Read more: https://bit.ly/3UT8GcQ

CDR-Life has announced that Chief Medical Officer Swethajit Biswas will co-lead a seminar on translational insights into cell engager drugs at the 6th Annual Cell Engager Summit on May 21 in Boston. cdr-life.com/news/

Congrats to @Amgen on FDA approval of the second ever T cell Engager therapy in solid tumors. It is so exciting to see great progress being made in the T cell engager space. https://lnkd.in/eTBNVygY